Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
Key Highlights
- ➤Q3 net sales $74,000, gross profit $40,000, approximately 54% margin
- ➤Cash resources $5.0 million; Dermata expects funding operations into Q1 2027
- ➤Tome Foundational Treatment launched August 25, generating first product revenue
- ➤Tome Clearing Treatment clinical trial initiated; launch expected in first half of 2027
- ➤Q3 net loss $2.8 million versus $1.7 million year over year
Expert Statements
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around Bioneedle(TM), our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“We are excited about the early interest in our Tome Foundational Treatment, including approximately 30% of orders generated via subscriptions.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“Importantly, our strategy extends beyond the launch of a single product.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“Recently, we initiated a clinical trial evaluating Tome Clearing Treatment, our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“Looking ahead, our priorities are focused on increasing brand awareness of Tome, converting consumer interest into sales, expanding our distribution opportunities, and building a broader portfolio of products powered by Bioneedle.”
Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics
“We believe our combination of clinical expertise, differentiated skincare technology, and direct-to-consumer commercialization provides an opportunity to build a growing skincare business with multiple potential revenue streams and create long-term value for our shareholders.”
SAN DIEGO, CA / ACCESS Newswire / November 10, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare products, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2026.
"The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around Bioneedle(TM), our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder. We are excited about the early interest in our Tome Foundational Treatment, including approximately 30% of orders generated via subscriptions. We believe our subscribers will help establish the foundation for a scalable business with opportunities to expand consumer awareness, develop recurring revenue through subscriptions, and introduce our products to skincare professionals."
Get started
Create a free account to read the full story.